{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MESOM", "query": { "condition": "MESOM" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 333, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MESOM&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T10:44:37.094Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02599194", "title": "18F-FSPG PET/CT for Cancer Patients on Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Neoplasm", "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Renal Cell Cancer", "Progesterone Receptor Negative", "Stage III Mesothelioma", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Mesothelioma", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "18F-FSPG", "type": "DRUG" }, { "name": "18F-FDG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrei Iagaru", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-07", "completion_date": "2016-12-14", "has_results": true, "last_update_posted_date": "2019-01-03", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02599194" }, { "nct_id": "NCT00535951", "title": "Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Mesothelioma" ], "interventions": [ { "name": "LBH589", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 4, "location_summary": "Fayetteville, Arkansas • Augusta, Georgia • Chicago, Illinois + 1 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00535951" }, { "nct_id": "NCT00459862", "title": "Pazopanib in Treating Patients With Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Mesothelioma", "Localized Malignant Mesothelioma", "Recurrent Malignant Mesothelioma" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pazopanib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-03", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-02-24", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459862" }, { "nct_id": "NCT03678350", "title": "Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Mesothelioma", "Non-Small Cell Lung Carcinoma", "Pleural Disorder" ], "interventions": [ { "name": "Light Dosimetry for Intranoperative Therapy", "type": "DEVICE" }, { "name": "Photodynamic Therapy", "type": "PROCEDURE" }, { "name": "Porfimer Sodium", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "PROCEDURE", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-09-17", "completion_date": "2025-10-09", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03678350" }, { "nct_id": "NCT03507452", "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma", "Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma", "Advanced Recurrent Serous Ovarian Cancer", "Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)" ], "interventions": [ { "name": "BAY2287411", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-06-13", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03507452" }, { "nct_id": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Pleural Disease", "Mesothelioma", "Metastases", "Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "iCasp9M28z T cell infusions", "type": "GENETIC" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2015-05", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414269" }, { "nct_id": "NCT00027508", "title": "Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2015-02-24", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027508" }, { "nct_id": "NCT02859415", "title": "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Neoplasms", "Lung Neoplasms", "Mesothelioma", "Thymus Neoplasms", "Neoplasms, Germ Cell and Embryonal" ], "interventions": [ { "name": "Mithramycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-08-08", "completion_date": "2021-12-01", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859415" }, { "nct_id": "NCT06535607", "title": "Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)", "Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)", "Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)", "Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)", "Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)" ], "interventions": [ { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2024-08-22", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06535607" }, { "nct_id": "NCT00003723", "title": "S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "1999-02", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-10-08", "last_synced_at": "2026-06-25T10:44:37.094Z", "location_count": 84, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003723" } ] }